ResMed Inc (ASX:RMD) Chairman and Chief Executive Officer Michael J. Farrell disposed of a total of 8,111.385 shares of ResMed common stock on 11 November 2026 to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted across three separate years, according to a Form 4 filed with the United States Securities and Exchange Commission.
Key Points
- Michael J. Farrell disposed of 3,465.749 shares at $234.11 for tax withholding on RSUs granted 16 November 2023
- A further 2,209.793 shares were disposed of at $234.11 for tax withholding on RSUs granted 20 November 2024
- An additional 2,435.843 shares were disposed of at $234.11 for tax withholding on RSUs granted 20 November 2025
- Following all reported transactions, Farrell directly holds 471,774 shares of ResMed common stock
- Farrell also holds 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust
Tax Withholding Disposals Across Three RSU Grant Tranches
All three disposals on 11 November 2026 were made to the issuer and classified under transaction code "F", indicating shares surrendered for tax withholding purposes on vesting Restricted Stock Units. The shares disposed of were priced at $234.11 each across all three transactions. The RSU grants covered in the disposals were originally made on 16 November 2023, 20 November 2024, and 20 November 2025 respectively, with each vesting event triggering a separate withholding transaction recorded on the same date.
Beneficial Ownership Following Reported Transactions
Following the three disposal transactions, Michael J. Farrell directly holds 471,774 shares of ResMed common stock, according to the filing. The filing notes that this figure includes 82.2684 shares of ResMed stock purchased on 30 October 2026 through the ResMed Employee Stock Purchase Plan. In addition to his direct holdings, Farrell maintains an indirect beneficial ownership of 2,090 shares held through the Lisette and Michael Farrell Family Trust, as disclosed in Table I of the Form 4.
Filing Details and Signatory
The Form 4 statement of changes in beneficial ownership was filed with the SEC pursuant to Section 16(a) of the Securities Exchange Act of 1934. The date of the earliest transaction reported is 11 November 2026, and the form was signed by Michael J. Farrell in his capacity as Chairman and CEO on 13 November 2026. The filing identifies Farrell as both a Director and Officer of ResMed Inc, and the form was filed by one reporting person. No derivative securities transactions were reported in Table II of the filing.





Please wait processing your request...